The Role of Human Insulin Growth Factor (Igf) – Axis in Carcinogenesis

Kwaśniewski, Wojciech; Kotarski, Józef; Polak, Grzegorz; Goździcka-Józefiak, Anna; Kotarski, Jan

doi:10.2478/acb-2014-0002

Abstract

The human insulin-like growth factor (IGF) system has attracted significant researcher interest due to its endocrine and autocrine / paracrine activities, mitogenic effects and the involvement in the regulation of proliferation, differentiation and apoptosis. The signaling pathways used by the IGF system impact cellular metabolism in a complex manner complex and many details are still unclear. Understanding the molecular mechanism of action of IGF’s and their effects on cellular activity may provide a basis to develop new anticancer drugs. This review focuses on recent studies that expand our knowledge of the signaling pathways of IGF system

References

[1] Alami N, Page V, Yu Q, Jerome L, Paterson J, Shiry L, Leyland-Jones B. Recombinant human insulin -like growth factor- binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res 2008; 18: 487-496.10.1016/j.ghir.2008.04.00218502161
Search in Google Scholar
[2] Akkiprik M, Hu L, Sahin A, Hao X, Zhang W. The subcellular localization of IGFBP5 affects its cell growth and migration functions in breast cancer. BMC Cancer 2009; 9: 103. doi:10.1186/1471-2407-9-10310.1186/1471-2407-9-103267031619341485
Search in Google Scholar
[3] Attias-Geva ZA, Bentov I, Ludwig DL , Fishman A , Bruchim I, Werne H. Insulin-like growth factor -I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMCA12) inhibits IGF-I action in endometrial cancer cells. Eur. J Cancer 2011; 47: 1717-1726.
Search in Google Scholar
[4] Atzori F, Tabernero J, Cervan tes A, Prudkin L, Andreu J, Rodríguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E., Roselló S, Langdon RB, Baselga J. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 6304-6312.10.1158/1078-0432.CCR-10-333621810918
Search in Google Scholar
[5] Avruch J. MAP kinase pathawy: the first twenty years. Bioch Physiol Acta 2010; 1773: 1150-1160.
Search in Google Scholar
[6] Baraniak AP, Chen JR, Garcia-Blanco A. Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice. Mol Cell Biol. 2006; 26: 1209-1222.10.1128/MCB.26.4.1209-1222.2006136717816449636
Search in Google Scholar
[7] Barton ER. The ABC of IGF-I isoforms: impact on muscle hyprtrophy and implication for repair. App. Physiol. Nutr. Metab. 2006; 31: 791-797.10.1139/h06-05417213901
Search in Google Scholar
[8] Barton ER, DeMeo J, Lei H. The insulin-like growth factor (IGF-I) E-peptydes are required for isoform specific gene expression and muscle hypertrophy after local IGF-I production. J Appl Physiol. 2010; 108: 1069-1076.10.1152/japplphysiol.01308.2009286754620133429
Search in Google Scholar
[9] Baserga R. Customizing the targeting of IGF-1 receptor. Future Oncol 2009; 5: 43-50.10.2217/14796694.5.1.4319243297
Search in Google Scholar
[10] Becker MA, Ibrahim YH, Cui X, Lee AU, Yee D. The IGF pathway regulates ER alpha through a S6K1dependent mechanism in breast cancer cells. Mol.Endocrinol 2011; 3: 516-528.
Search in Google Scholar
[11] Belizon A, Balik E, Kirman I, Remotti H, Ciau N, Jain S, Whelan RL. Insulin-like growth factor binding protein-3 inhibits colitis-induced carcinogenesis. Dis Colon Rectum 2007; 50: 1377-83.10.1007/s10350-007-0258-x17668267
Search in Google Scholar
[12] Benyoucef S, Surinya KH, Hadaschik D, Siddle K. Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem J 2007; 40: 603-13.10.1042/BJ20061709187638417291192
Search in Google Scholar
[13] Bouskila M, Hunter RW, Ibrahim AF, Delattre L, Peggie M, van Diepen JA, Voshol PJ, Jensen J, Sakamoto K. Allosteric regulation of glycogen synthesis controls glycogen in muscle. Cell Metabolism 2010; 12: 456-466.10.1016/j.cmet.2010.10.00621035757
Search in Google Scholar
[14] Bracko O, Singer T, Aigner S, Knobloch M, Winner B, Ray J, Clemenson GD Jr, Suh H, Couillard -Despres S, Aigner L, Gage FH, Jessberger S. Gene expression profiling of neural stem cells and their neuronal progeny reveals IGF2 as a regulator of adult hippocampal neurogenesis. J Neurosci. 2012 7; 32: 3376-3387.10.1523/JNEUROSCI.4248-11.2012
Search in Google Scholar
[15] Brown J, Jones EY, Forbes BE. Keeping IGF-II under control: lessons from the IGF-II-IGF2R crystal structure. Trends Biochem Sci 2009; 34: 612-619.10.1016/j.tibs.2009.07.003
Search in Google Scholar
[16] Butt AJ, Dickson KA, McDougall F, Baxter RC. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 2003; 278(32): 29676-2985.10.1074/jbc.M301965200
Search in Google Scholar
[17] Carapan cea M, Cosaceanu D, Budiu R, Kwiecinska A, Tataranu L, Ciubotaru V, Alexandru O, Banita M, Pisoschi C, Bäcklund ML, Lewensohn R, Dricu A. Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells. J Neurooncol 2007; 85: 245-254.10.1007/s11060-007-9417-0
Search in Google Scholar
[18] Clemmons DR. Physiology of insulin-like growth factor I. www.uptodate.com /contens/physiology of insulin growth factor /2012. JOURNAL
Search in Google Scholar
[19] Clemmons DR. Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2006; 2: 436-446.10.1038/ncpendmet0244
Search in Google Scholar
[20] Clemmons DR. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol 2006; 6: 620-630.10.1016/j.coph.2006.08.006
Search in Google Scholar
[21] Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.10.1016/S0092-8674(00)80405-5
Search in Google Scholar
[22] DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, Canalis E, Rosen CJ. Gender-specific changes in bone turnover and skeletal architecture in IGFBP-2-null mice. Endocrinology 2008; 149: 2051-2061. 10.1210/en.2007-1068232926218276763
Search in Google Scholar
[23] Di Cosimo S, Bendell JC, Cervan tes-Ruiperez A. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol 2010; 28(Suppl 15): 3008.10.1200/jco.2010.28.15_suppl.3008
Search in Google Scholar
[24] Durai R, Yang SY, Sales KM, Seifa lian AM, Goldspink G, Winslet MC: Insulin-like growth factor binding protein-4 gene therapy increases apoptosis by altering Bcl-2 and Bax proteins and decreases angiogenesis in colorectal cancer. Int J Oncol 2007; 30: 883-888.10.3892/ijo.30.4.883
Search in Google Scholar
[25] Durai R, Yang SY, Seifa lian AM, Goldspink G, Winslet MC. Role of insulin-like growth factor binding protein-4 in prevention of colon cancer. World J Surg Oncol 2007; 5: 128-136.10.1186/1477-7819-5-128220399917988381
Search in Google Scholar
[26] Durai R, Yang SY, Sales KM, Seifa lian AM, Goldspink G,Winslet MC. Increased apoptosis and decreased proliferation of colorectal cancer cells using insulin-like growth factor binding protein-4 gene delivered locally by gene transfer. Colorectal Dis 2007; 9: 625-635.10.1111/j.1463-1318.2006.01190.x17824980
Search in Google Scholar
[27] Dziadziuszko R, Merrick DT, Witta SE. Insulin-like growth factor receptor 1(IGF1R) gene copy number is associated with survival in operable non-smallcell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010; 28: 2174-2180.10.1200/JCO.2009.24.6611286043520351332
Search in Google Scholar
[28] Ester WA, Hokken-Koelega AC. Polymorphisms in the IGF1 and IGF1R genes and children born small for gestational age: results of large population studies. Best Pract Res Clin Endocrinol Metab 2008; 22: 415-431.10.1016/j.beem.2008.03.00118538283
Search in Google Scholar
[29] Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R: The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008; 114: 23-37.10.1080/1381345080196971518465356
Search in Google Scholar
[30] Gariboldi MB, Rav izza R, Monti E. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 2010; 80: 455-462.10.1016/j.bcp.2010.05.01120488164
Search in Google Scholar
[31] Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, Sagar M, Wong TW, Gottardis MM, Erlichman C. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008; 7: 2589-2598.10.1158/1535-7163.MCT-08-0493261431618765823
Search in Google Scholar
[32] Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Phase I dose escalation study of the anti insulin-like growth factor- i receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 5834-5840.10.1158/1078-0432.CCR-07-111817908976
Search in Google Scholar
[33] Heidegger I, Pircher A, Klocker H, Massoner P. Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Therapy 2011; 11: 701-707.10.4161/cbt.11.8.1468921311212
Search in Google Scholar
[34] Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor binding protein (IGFBP) superfamily Endocrine Reviev 1999; 20: 761-787.10.1210/edrv.20.6.038210605625
Search in Google Scholar
[35] Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009; 37: 217-22.10.1042/BST0370217
Search in Google Scholar
[36] Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, Biessy C, Tjønneland A, Olsen A, Overva d K, Grønbaek H, Clav el-Chapelon F, Boutron-Ruault MC, Linseisen J, Boeing H, Pischon T, Trichopoulos D, Oikonomou E, Trichopoulou A, Panico S, Vineis P, Berrino F, Tumino R, Masala G, Peters PH, van Gils CH, Bueno-de-Mesquita HB, Ocké MC, Lund E, Mendez MA, Tormo MJ, Barricarte A, Martínez-García C, Dorronsoro M, Quirós JR, Hallmans G, Palmqvist R, Berglund G, Manjer J, Key T, Allen NE, Bingham S, Khaw KT, Cust A, Kaaks R. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007; 121: 368-376.10.1002/ijc.22697
Search in Google Scholar
[37] Ji QS, Mulvihill MJ, Rosenfeld-Franklin M. A novel, potent, and selective insulin-like growth factor- i receptor kinase inhibitor blocks insulin-like growth factor-i receptor signaling in vitro and inhibits insulin-like growth factor-i receptor dependent tumor growth in vivo. Mol Cancer Ther 2007; 6: 2158-2167.10.1158/1535-7163.MCT-07-0070
Search in Google Scholar
[38] Jozefiak A, Pacholska-Bogalska J, Myga-Nowa k M, Kedzia W, Kwa sniewska A, Luczak M, Kedzia H, Gozdzicka-Jozefiak A. Serum and tissue levels of insulin-like growth factor-I in women with dysplasia and HPV-positive cervical cancer. Mol Med Report. 2008; 1: 231-237.
Search in Google Scholar
[39] Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003; 13: 113-170.10.1016/S1096-6374(03)00038-8
Search in Google Scholar
[40] Kang HJ, Yi YW, Kim HJ, Hong YB, Seong YS, Bael J. BRCA1 negatively regulated IGF 1 expression thgrough an estrogen-responsive element-like site, Cell Death.Dis. 2012; 28: 3-15. doi:10.1038/ cddis.2012.78.10.1038/cddis.2012.78
Search in Google Scholar
[41] Key TJ, Appleby PN, Reeves GK. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010; 11: 530-542.10.1016/S1470-2045(10)70095-4
Search in Google Scholar
[42] Knowlden JM, Jones HE, Barrow D. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for gefitinib (’Iressa’) response and resistance. Breast Cancer Res Treat 2008; 111: 79-91.10.1007/s10549-007-9763-917902048
Search in Google Scholar
[43] Kotronen A, Lewitt M, Hall K, Brismar K, Yki-Järvinen H. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab 2008; 93: 4867-4872.10.1210/jc.2008-124518796514
Search in Google Scholar
[44] Laursen LS, Kjaer-Sorensen K, Andersen MH. Regulation of insulin-like growth factor (IGF) bioactivity by sequential proteolytic cleavage of IGF binding protein-4 and -5. Mol Endocrinol 2007; 21:1246-1257.10.1210/me.2006-052217312271
Search in Google Scholar
[45] Liu BA, Jablonowski K, Shah EF, Engelmann BW, Jones RB, Nash PD. SH2 domains recognize contexual peptide sequence information to determine selectivity. Mol Cell Proteomics 2010;9: 2391-2404. doi:10.1074/mcp/M110.001586.
Search in Google Scholar
[46] Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 2007; 26: 1811-1819.10.1038/sj.onc.120997716983336
Search in Google Scholar
[47] Ma J, Sawa i H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, Wakasugi T, Funahashi H, Sato M, Takeyama H. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. J Surg Res 2010; 160: 90-101.10.1016/j.jss.2008.08.016
Search in Google Scholar
[48] Mairet-Coello G, Tury A, DiCicco-Bloom E. Insulin-like growth factor-1 promotes G(1)/S cell cycle progression through bidirectional regulation of cyclins and cyclin-dependent kinase inhibitors via the phosphatidylinositol 3-kinase/Akt pathway in developing rat cerebral cortex. J Neurosci 2009; 29: 775-788.10.1523/JNEUROSCI.1700-08.2009
Search in Google Scholar
[49] Maloney EK, McLaughlin J, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blatter WA, Chittenden T, Singh R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proloferation. Cancer Res 2003; 63: 5073-5083.
Search in Google Scholar
[50] Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen Dürr P, Klocker H. Novel mechanism of IGF- binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion and motility. Endocr Relat Cancer 2009; 16: 795-808.10.1677/ERC-08-0175
Search in Google Scholar
[51] Matheny RW Jr, Nindl BC, Adamo LA. A putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology 2010; 151: 865-875.10.1210/en.2009-1217
Search in Google Scholar
[52] Mita K, Zhang Z, Ando Y, Toya ma T, Hamaguchi M, Kobaya shi S, Haya shi S, Fujii Y, Iwa se H, Yamashita H. Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol 2007; 37: 575-582. 10.1093/jjco/hym066
Search in Google Scholar
[53] Musaro A., Dobrowolny G., Rosenthal N. The neuroprotective effects of a locally acting IGF-I isoform. Ex Gerontol. 2007; 42: 76-80.10.1016/j.exger.2006.05.004
Search in Google Scholar
[54] Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P. Safet y, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010; 11: 129-135.10.1016/S1470-2045(09)70354-7
Search in Google Scholar
[55] Pacholska-Bogalska J, Józefiak A, Nowa k W, Kedzia W, Kwaśniewska A, Goździcka-Józefiak A. Association of the IGF-I promoter P1 polymorphism with risk of cervical cancer. Eur J Gynaecol Oncol. 2011; 32: 393-408.
Search in Google Scholar
[56] Pandini G, Wurch T, Akla B, Corva ia N, Belfiore A, Goetsch L. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 2007; 43: 1318-1327.10.1016/j.ejca.2007.03.00917451939
Search in Google Scholar
[57] Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chaw la SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011; 29: 4541-4547.10.1200/JCO.2010.34.0000323665422025149
Search in Google Scholar
[58] Pearce CL, Doherty JA, Van den Berg DJ, Moysich K, Cushing-Haugen KL, Conti DV, Ramus SJ, Gentry-Maharaj KL, Menon U, Gay ther SA, Pharoah PD, Song H, Kjaer SK, Hogdall E, Hogdall C, Whitemorre AS, Mc Guire V, Sieh W, Grunwa ld J, Madrek K, Jakubowska A, Lublinski J, Trench GC, AOCS/ASC Study Group, Beesley J, Webb PM, Berschuk A, Schildkraut JM, Iversen ES, Moorman PG, Edlund CK, Stram DO, Pike MC, Ness RB, Wu AH: Genetic variation in insulin -like growth factor-2 may play a role in ovarian cancer risk. Hum Mol Genetics 2011; 20: 2263-2272.10.1093/hmg/ddr087309018821422097
Search in Google Scholar
[59] Philippou A, Halapa s A, Maridaki M, Koutsilieris M. Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact 2007; 7: 208-215.
Search in Google Scholar
[60] Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 2008; 12: 915-928.10.1038/nrc253619029956
Search in Google Scholar
[61] Price AJ, Allen NE, Appleby PN, Crowe FL, Trav is RC, Tipper SJ, Overva d K, Grønbæk H, Tjønneland A, Johnsen NF, Rinaldi S, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Trichopoulou A, Trichopoulos D, Andarakis G, Palli D, Krogh V, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Argüelles MV, Sánchez MJ, Chirlaque MD, Barricarte A, Larrañaga N, González CA, Stattin P, Johansson M, Khaw KT, Wareham N, Gunter M, Riboli E, Key T. Insulin-like Growth Factor-I Concentration and Risk of Prostate Cancer: Results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2012; 2: 1531-1541.10.1158/1055-9965.EPI-12-0481-T574960922761305
Search in Google Scholar
[62] Rajpa thak SN, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, Muzumdar R, Rohan TE, Strickler HD. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev 2009; 25: 3-12. 10.1002/dmrr.919415341419145587
Search in Google Scholar
[63] Rajski M, Zanetti-Dallenbach R, Vogel B, Herrmann R, Rochlits Ch, Buess M. IGF 1 induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Medicine 2010; 8: www.biomedcentral.com/1741-7051/8/110.1186/1741-7015-8-1282365220051100
Search in Google Scholar
[64] Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Dav is N, Hollywood E, Shia J, Schwa rtz J, Chandrawan sa K, Dontabhaktuni A, Youssoufian H, Solit DB, Saltz LB. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 2010; 28: 4240-4246.10.1200/JCO.2010.30.4154329666820713879
Search in Google Scholar
[65] Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, Boeing H, Pischon T, Panico S, Agnoli C, Palli D, Tumino R, Vineis P, Peeters PH, van Gils CH, Bueno-de-Mesquita BH, Vrieling A, Allen NE, Roddam A, Bingham S, Khaw KT, Manjer J, Borgquist S, Dumeaux V, Torhild Gram I, Lund E, Trichopoulou A, Makrygiannis G, Benetou V, Molina E, Donate Suárez I, Barricarte Gurrea A, Gonzalez CA, Tormo MJ, Altzibar JM, Olsen A, Tjonneland A, Grønbaek H, Overva d K, Clav el-Chapelon F, Boutron-Ruault MC: Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2010; 126: 1702-1715.10.1002/ijc.2492719810099
Search in Google Scholar
[66] Rho SB, Dong SM, Kang S, Seo SS, Yoo CW, Lee DO, Woo JS, Park SY. Insul in-l ike gr owt h factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149: 461-471. 10.7326/0003-4819-149-7-200810070-00006258486918838726
Search in Google Scholar
[67] Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. Early drug development of inhibitors of the insulin -like growth factor-ireceptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008; 7: 2575-2588.10.1158/1535-7163.MCT-08-0265310187018790742
Search in Google Scholar
[68] Sakauchi F, Nojima M, Mori M. Serum insulin-like growth factors I and II, insulin-like growth factor binding protein-3 and risk of breast cancer in the Japan Collaborative Cohort study. Asian Pac J Cancer Prev 2009; 10: 51-55.
Search in Google Scholar
[69] Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrinol Rev 2007; 28: 20-47.10.1210/er.2006-000116931767
Search in Google Scholar
[70] Santosh V, Arivaz hagan A, Sreekanthreddy P, Sriniva san H, Thota B, Srividya MR, Vrinda M, Sridevi S, Shailaja BC, Samuel C, Prasanna KV, Thennarasu K, Balasubramaniam A, Chandramouli BA, Hegde AS, Somasundaram K, Kondaiah P, Rao MR. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol Biomarkers Prev 2010; 19: 1399-1408.10.1158/1055-9965.EPI-09-121320501753
Search in Google Scholar
[71] Scicchitano BM, Rizzuto E, Musaro A. Counteracting muscle casting in aging and neuromuscular dis eses: the critical role of IGF-I. Aging (Albany NY) 2009; 1: 451-457.10.18632/aging.100050280602520157530
Search in Google Scholar
[72] Schlenska-Lange A, Knüpfer H, Lange TJ, Kiess W, Knüpfer M. Cell proliferation and migration in glioblastoma multiforme cell lines are influenced by insulin-like growth factor I in vitro. Anticancer Res 2008; 28: 1055-1060.
Search in Google Scholar
[73] Schütt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004; 32: 859-868.10.1677/jme.0.032085915171717
Search in Google Scholar
[74] Siddle K. Signaling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 2011; 47: R1-R10. DOI:10.1530/JME/11-0022.www.endockrinology-journals.org??
Search in Google Scholar
[75] Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T., Goshizky ML, Marks JR, Wang XF. Acquired expression of periostin by human breast cancer promoters tumor angiogenesis through up -regulation of vascular endothelial growth receptor 2 expression, Mol Cell Biol 2004; 24: 3992-4003.
Search in Google Scholar
[76] Song R. X-D,Chen Y, Zhang Z, Bao Y, Yue W , Wang J-P. Estrogen utilization of IGF-I-R and EGF-R to signal in breast cancer cells. J Steroid Bioch Mol Biology 2010; 118: 219-230.10.1016/j.jsbmb.2009.09.018282650619815064
Search in Google Scholar
[77] Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci U S A 2008; 105: 19378-19383.10.1073/pnas.0809223105261476919033454
Search in Google Scholar
[78] Suzuki S, Kojima M, Tokudome S et al. Insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein-3, and risk of colorectal cancer: a nested case-control study in the Japan Collaborative Cohort study. Asian Pac J Cancer Prev 2009; 10: 45-49.
Search in Google Scholar
[79] Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M, Tolcher A. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012 May 20; 30: 1849-1856.10.1200/JCO.2011.37.235922508822
Search in Google Scholar
[80] Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) in vivo. FASEB J 2009; 23: 2616-2626.10.1096/fj.08-11412419332648
Search in Google Scholar
[81] Wallis M. New insul in- l ike gr owt h fact or (IGF) -pr ecur sor sequences fr om mammal ian genomes: the molecular evolution of IGFs and associated peptides in primates. Growth Hor IGF Res 2009; 19: 12-2310.1016/j.ghir.2008.05.00118571449
Search in Google Scholar
[82] Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 2008;14: 261-267.10.1111/j.1524-4741.2008.00572.x18373644
Search in Google Scholar
[83] Wang GK, Hu L, Fuller GN, Zhang W. An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2- induced cell mobility. J Biol Chem 2006; 281: 14085-14091. 10.1074/jbc.M51368620016569642
Search in Google Scholar
[84] Werner H, Weinstein D, Bentov I. Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem 2008; 114: 17-22.10.1080/1381345080190069418465355
Search in Google Scholar
[85] Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 2009; 115: 58-71.10.1080/13813450902783106
Search in Google Scholar
[86] Weroha S, Haluska P. IGF-1 receptor inhibitors in clinical trials - early lessons. J Mamm Gland Biol Neoplasia 2008; 13: 471-483.10.1007/s10911-008-9104-6
Search in Google Scholar
[87] Weroha SJ, Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am. 2012; 41: 335-350.10.1016/j.ecl.2012.04.014
Search in Google Scholar
[88] Yamada PM, Lee KW. Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol 2009; 296: 954-976.10.1152/ajpcell.00598.2008
Search in Google Scholar
[89] Yang SY, Goldspink G. Different role of the IGF-1 Ec peptide (MGF) and mature IGF-1 in myoblast proliferation and differentiation, FEBS Letters 2002; 522: 156-16010.1016/S0014-5793(02)02918-6
Search in Google Scholar
[90] Yang SY, Sales KM, Fuller B, Seifa lian AM, Winslet MC. Apoptosis and colorectal cancer: implications for therapy.Trends Mol Med 2009; 15: 225-233.10.1016/j.molmed.2009.03.00319362056
Search in Google Scholar
[91] Yang SY, Miah A, Pabari A, Winslet M. Growth factors and their receptors in cancer metastases. Front Biosci 2011; 16: 531-538.10.2741/370321196186
Search in Google Scholar
[92] Yang SY, Sales KM, Fuller BJ, Seifa lian AM, Winslet MC. Inducing apoptosis of human colon cancer cells by an igf-I D domain analogue peptide. Mol Cancer 2008; 7: 17-27.10.1186/1476-4598-7-17227651318261206
Search in Google Scholar
[93] Zhu W, Shiojima I, Ito Y, Li Z, Ikeda H, Yoshida M, Naito AT, Nishi J, Ueno H, Umezawa A, Minamino T, Nagai T, Kikuchi A, Asashima M, Komuro I. IGFBP-4 is an inhibitor of canonical WNT signaling required for cardiogenesis. Nature 2008; 454: 345-359. 10.1038/nature0702718528331
Search in Google Scholar

The Role of Human Insulin Growth Factor (Igf) – Axis in Carcinogenesis

Abstract

Paradigm

My account